Clinical development failure
Pipeline value depends on successful late-stage data for setrusumab and alvelestat.
- Scope
- Lead rare-disease programs
- Materiality
- high
Mereo BioPharma Group plc
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing late-stage therapies for rare diseases. Its pipeline centers on setrusumab for osteogenesis imperfecta, alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease, and a partnered early-stage bone disease program, with development funded through collaborations, licensing, and equity financing.
−7 990,0 %
−8 375,6 %
10.46
10.46
| % | |
|---|---|
| Rare disease clinical programs | 0% Late-stage and early-stage drug candidates being developed for orphan and rare indications. |
| Setrusumab program | 0% Bone-disease asset for osteogenesis imperfecta with multiple regulatory designations. |
| Alvelestat program | 0% Candidate for severe alpha-1 antitrypsin deficiency-associated lung disease. |
| Partnered and licensed assets | 100% Programs monetized through collaborations, milestones, and regional rights retention. |
Mereo does not sell approved commercial products; its economic counterparties are pharmaceutical partners, licensees,...
- Pharmaceutical collaboration partnersprimary
Companies that license assets or share development costs and pay milestones, such as ReproNovo and Ultragenyx.
- Rare disease patients and specialist centersprimary
Small, concentrated patient populations treated at specialized sites for OI, AATD-LD, and bone disease.
- Clinical investigators and KOLssecondary
Physicians and trial sites that enroll patients, generate data, and support regulatory pathways.
- Patient advocacy groupssecondary
Organizations that help with awareness, trial recruitment, and disease education in rare indications.
Mereo is operationally international, with development and partnering activity spanning the U.S., Europe, and the U.K...
- •Headquartered in the United States
- •Development and partnering activity spans the U.S. and Europe
- •European commercial rights retained for vantictumab
- •Setrusumab commercialization planning focuses on Europe and the U.K.
- •Foreign currency exposure affects reported results
Mereo’s strategy is to acquire de-risked, data-rich rare-disease assets from larger pharma or biotech companies and...
01
Advance setrusumab toward approval and launch readinessshort-term
It is the most advanced rare-disease asset and a potential commercial anchor.
02
Progress alvelestat through development and regulatory stepsmedium-term
It broadens the pipeline into another orphan indication and diversifies value creation.
03
Monetize non-core assets through partnershipsshort-term
Milestones and out-licensing help fund operations without relying only on equity.
Mereo is still a development-stage biotech with no approved product sales, so its value depends on clinical success,...
Financing risk
The company expects to need additional external funding before commercialization.
- Scope
- Operations into 2027 and beyond
- Materiality
- high
Foreign currency volatility
The company reported significant foreign currency transaction losses and translation gains/losses.
- Scope
- International operations and cash balances
- Materiality
- medium
Partner and collaboration risk
Milestones and development progress depend on third-party partners and licensees.
- Scope
- ReproNovo, Ultragenyx, āshibio
- Materiality
- medium
Collaboration milestone revenue
The $0.5 million ReproNovo milestone drove all reported revenue in the period
Foreign currency translation and transaction effects
Foreign currency transaction losses were a major driver of period net loss
Warrant fair value accounting
Changes in fair value can materially affect reported profit or loss
R&D tax credits
Credits reduce net loss and can distort comparability across periods
: 28.4.2026